HealthMore in Health→
Eli Lilly’s $4.5 Billion Indiana Bet Expands the U.S. Pharma Manufacturing Buildout
Key Takeaways
- Eli Lilly plans $4.5 billion in manufacturing investments across Indiana.
- Endpoints frames the move within a broader wave of U.S. drugmaker projects.
- The investment reinforces manufacturing as a strategic priority in biopharma.
- Indiana stands to deepen its role as a major life-sciences production hub.
DE
DT Editorial Team··via endpoints.news